Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
CPIX

CPIX - Cumberland Pharmaceuticals Inc Stock Price, Fair Value and News

$1.25-0.05 (-3.85%)
Delayed as of 03 Dec 2024, 11:23 am ET
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

CPIX Price Action

Last 7 days

22.6%


Last 30 days

16.1%


Last 90 days

-3.7%


Trailing 12 Months

-22.6%

CPIX RSI Chart

CPIX Valuation

Market Cap

18.3M

Price/Earnings (Trailing)

-1.69

Price/Sales (Trailing)

0.5

EV/EBITDA

-0.14

Price/Free Cashflow

-11.48

CPIX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CPIX Fundamentals

CPIX Revenue

Revenue (TTM)

36.8M

Rev. Growth (Yr)

-9.92%

Rev. Growth (Qtr)

-7.75%

CPIX Earnings

Earnings (TTM)

-10.8M

Earnings Growth (Yr)

-46.48%

Earnings Growth (Qtr)

-41.58%

CPIX Profitability

EBT Margin

-29.32%

Return on Equity

-44.22%

Return on Assets

-14.1%

Free Cashflow Yield

-8.71%

CPIX Investor Care

Buy Backs (1Y)

1.50%

Diluted EPS (TTM)

-0.77

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202438.8M37.8M36.8M0
202340.1M40.7M39.3M39.6M
202236.6M37.9M41.2M42.0M
202139.6M39.1M37.9M36.0M
202034.0M34.2M36.5M37.4M
201932.2M34.5M35.6M34.4M
201837.4M35.8M30.5M29.3M
201734.9M36.2M38.6M41.2M
201632.6M31.1M32.0M33.0M
201537.5M36.7M34.8M33.5M
201429.9M32.5M35.7M36.9M
201348.9M43.6M37.6M32.0M
201250.7M48.7M48.2M48.9M
201146.4M50.1M50.9M51.1M
2010044.3M45.1M45.9M
200900043.5M
CPIX
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
 CEO
 WEBSITEcumberlandpharma.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES85

Cumberland Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Cumberland Pharmaceuticals Inc? What does CPIX stand for in stocks?

CPIX is the stock ticker symbol of Cumberland Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cumberland Pharmaceuticals Inc (CPIX)?

As of Mon Dec 02 2024, market cap of Cumberland Pharmaceuticals Inc is 18.25 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CPIX stock?

You can check CPIX's fair value in chart for subscribers.

Is Cumberland Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether CPIX is over valued or under valued. Whether Cumberland Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Cumberland Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CPIX.

What is Cumberland Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Dec 02 2024, CPIX's PE ratio (Price to Earnings) is -1.69 and Price to Sales (PS) ratio is 0.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CPIX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cumberland Pharmaceuticals Inc's stock?

In the past 10 years, Cumberland Pharmaceuticals Inc has provided -0.13 (multiply by 100 for percentage) rate of return.